Bristol Myers interested in buying Aurinia Pharma – Bloomberg News

This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEH9L14W_L.jpg

Aurinia’s shares closed up nearly 27% on the news, giving it a market capitalization of $3.59 billion, according to Refinitiv data.

The report said no final decision has been made and that Bristol Myers could opt out of a potential deal.

Both Bristol Myers and Aurinia declined to comment on the matter.

Aurinia sells a treatment for a kidney disorder called lupus nephritis and is testing out treatments for other autoimmune and kidney diseases, according to its website.

Add Comment